Our report is the first to illustrate the ability of a compound SCN5A mutation to mitigate a lethal phenotype (i.e. LQT3), while concurrently introducing a new phenotype (i.e. conduction abnormalities) and modulating pharmacotherapy (i.e. Class IB agents like mexiletine for LQT3). Here, SCN5A is linked to long QT syndrome 3.